Expertise

  • Expertise in Business and Law: Business Administration, Biotechnology Business Strategies, Comparative and International Law, International Business Law. (Expertise in Medicine and Science) Chemistry, Biochemical Pathology, Internal Medicine, Medical Oncology, Cell Biology, Differentiation and Maturation of Human Cancer Cells, Drug Resistance of Cancer Cells, Hematology, Cancer Medicine, with emphasis on Molecular Oncology and new biotherapies including stem cells, Molecular Biology and Molecular Genetics of Cancer and Stem Cells.

Research Interests

  • Technology and the Law, Competitiveness and International Competitiveness Laws , Biotechnology Innovation and Business Strategies, Transnational Commercial Law, Regulatory Laws in Biotech Products and Medical Malpractice, Global Competitive Strategies and in Biotech Manufacturing , Marketing and Distribution-    Innovative technologies in Molecular Biology, Stem Cell Growth and Cell Differentiation, Personalized Molecular Medicine and Cellular Therapy  for Cancer and Degenerative  Diseases, Stem Cell Basic Science and Clinical Applications, Research in the Differentiation and Maturation of Human Cancer Cells, Lung Cancer Differentiation, Drug Resistance in Oncology

 

Back to Adjunct Faculty

Samuel D. Bernal, PhD, MD, MBA, JD, LLM

Adjunct Faculty
Department of Finance, Accounting and Economics

Academic Background

  • Chemistry, University of Illinois  (USA)
  • Biochemical Pathology,  University of Chicago (USA)
  • School of Medicine, University of Chicago (USA)
  • Loyola Law School, Loyola University, Los Angeles (USA)
  • Grazadio Business School-Presidential MBA, Pepperdine University (USA)
  • LLM Center for International Legal Studies, Lazarski University (USA)
     

Professional Experience- Academic Appointments 

  • Professor of Medicine, Emeritus, UCLA School of Medicine (2003-Present)    
  • Professor of Medicine, UCLA School of Medicine (1994-2003)            
  • Associate Professor of Medicine, UCLA School of Medicine, (1992-1994)
  • Associate Professor of Medicine, Boston University School of Medicine (1989-1992)
  • Assistant Professor of Medicine, Harvard Medical School (1983-1989)   
  • Instructor in Medicine, Harvard Medical School (1981-1983)

Professional Experience- Adjunct and Visiting Professorships

  • Far Eastern Federal University School of Law, Vladivostok, Russia (2016-Present)
  • Ateneo de Manila University, College of Science, Department of Chemistry (2012-Present)
  • University of Santo Tomas, School of Medicine, Manila, Philippines (1997-2012)

Professional Experience- Academic Appointments  

  • Attending Physician, Division of Hematology and Oncology, Cedars-Sinai Medical Center (2002-Present)    
  • Adviser and Consultant, Technology and Innovation, Institute of Personalized Molecular Medicine, The Medical City, Manila, Philippines (2012-Present)
  • Director, Cancer Center, Greater Los Angeles VA Health System (2000-2003)
  • Chief, Division of Hematology and Oncology, U.C.L.A. San Fernando Valley Program (1992-2003)
  • Attending Physician, University Hospital, Boston University Medical School (1989-1992)
  • Associate Physician, Dana-Farber Cancer Institute, Harvard Medical School (1983-1989)
  • Associate Physician, Brigham and Womens Hospital, Harvard Medical School (1983-1989)
  • Clinical Associate in Medicine, Dana-Farber Medical School, Harvard Medical School (1981-1983)
  • Clinical Associate in Medicine, Brigham and Womens Hospital, Harvard Medical School (1981-1983)

Professional Experience- Legal Practice

  • Principal Lawyer, Law Offices of Bernal and Associates
    Woodland Hills, CA, USA
    Intellectual Property, Medical Malpractice
  • Law Adviser, GlobeTek Law, International Commercial
    Makati City, Philippines
    Technology Law, Regulatory Law
  • Commercial Lawyer, GlobeTek Law, International Prague,
    Czech Republic
    International Business, Regulatory Law

Affiliations, Awards, and Honors

  • Professor Emeritus of Medicine at UCLA 
  • Scientific Adviser for the Institute of Personalized Molecular Medicine (IPMM) at The Medical City
  • Visiting Professor of Science at the Ateneo School of Science and Engineering
  • Member of the ASEAN Law Association and the International Law Association
  • Founder and Chairman of GlobeTek Pro International
  • President, LA-Boston BioResearch Fund, Los Angeles, California, USA
  • President, GlobeTekPro, based in Prague, Czech Republic
  • President, Daba International Technology Company, based in Riga, Latvia
  • Chairman, GlobeTek Science Foundation, based in Manila, Philippines
  • President of Science and Technology Action Network for Development (STAND) based in Manila, Philippines and Prague, Czech Republic
  • Chairman of the International Institute of Law and Medicine (IILM) based in Salzburg, Austria
  • President of the Philippine Association in Europe, based in Prague, Czech Republic
  • Legal Counsel and Co-Founder, Global Filipino Diaspora, Los Angeles, California, USA
  • Visiting Professor of Law, Far Eastern Federal University, Vladivostok, Russia
  • Adjunct Professor of Business Management, Asian Institute of Management, Manila Philippines
     

Select Publications

  • Lutz RP, Bernal SD, Boggio RA, Harris RO and Nicholas MW. 
    Dual reaction pathways in an open-chain cope rearrangement, Am Chem Soc. 1971;93:3985-3990.
  • Bernal SD, Blumberg BM and Nakamoto T. 
    Requirement of initiation factor IF-3 in the initiation of polypeptide synthesis with N-acetylphenyalanyl-tRNA. Proc Nat Acad Sci. 1974;71:774-778.
  • Bernal SD, Blumberg BM, Wang JJ and Nakamoto T.
    Participation of initiation factor IF-3 in the binding of AcPhe-tRNA to the 30S ribosomal subunit. Biochim Biophys Res Commun. 1974;60:1127-1133.
  • Blumberg BM, Bernal SD and Nakamoto T.
    Inhibition of N-acetylphenylalanyl-tRNA binding to 30S ribosomal subunit of E. coli by N-formylmethionyl-tRNA. Biochemistry.1974;13:3307-3311.
  • Bernal SD, Shapiro HM, and Chen LB.
    Monitoring the effect of anticancer drugs of L1210 cells by a mitochondrial probe, rhodamine-123. Int J of Cancer, 1982;30:3307-3311.
  • Chen LB, Summerhayes IC, Johnson LV, Walsh ML, Bernal SD and Lampidis TJ.
    Probing mitochondria in living cells with rhodamine 123. Cold Spring Harbor Symposium. 1982;46:141-155.
  • Summerhayes IC, Lampidis TJ, Bernal SD and Chen LB.
    Unusual retention of rhodamine 123 in carcinoma cells. Proc Acad Sci 1982;70:5292-5296.
  • Lampidis TJ, Bernal SD, Summerhayes IC and Chen LB.
    Selective toxicity and preferential retention of Rh-123 in carcinomas. Ann NY Acad Sci. 1982;42;512-516.
  • Bernal SD, Lampidis TJ, Summerhayes IC and Chen LB.
    Rhodamine-123 selectively reduces clonogenic growth of carcinoma cells in vitro. Science. 1982;218:1117-1119.
  • Lampidis TJ, Bernal SD, Summerhayes IC, and Chen LB.
    Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Research. 1983;43:716-720.
  • Bernal SD and Chen LB.
    Induction of cytoskeleton-associated proteins during differentiation of  human myeloid leukemic cell lines. Cancer Res. 1982;42:5106-5116.
  • Baylin SB, Gazdar AF, Minna JD, Bernal SD and Shaper JH.
    A unique cell surface protein phenotype distinguishes human small cell from non small cell lung cancer. Proc Nat Acad Sci. 1982;70:4650-4654.
  • Francis J, Thompson R, Bernal SD, Luk G and Baylin S.
    Effects of dibutyryl cyclic AMP on the growth of cultured human small cell carcinoma and the specific cellular activity of 1-DOPA decarboxylase. Cancer Res. 1983;43:639-645.
  • Bernal SD, Thompson R and Baylin SB.
    In vitro and in vivo growth characteristics of two different cell populations in an established line of human neuroblastoma. Cancer Res. 1983;43:1256-1260.
  • Bernal SD, Baylin SB, Shaper JH, Gazdar AF and Chen LB.
    Cytoskeleton-associated proteins of human lung cancer cells. Cancer Res. 1983;43:1798-1808.
  • Bernal SD, Lampidis TL, McIsaac B and Chen LB.
    Anticarcinoma activity in vivo of a mitochondrial specific inhibitor, rhodamine 123. Science. 1983;222:169-172.
  • Chen LB, Summerhayes IC, Nadakavukaren KK, Lampidis TJ, Bernal SD and Shepherd EL.
    Mitochondria in tumor cells: Effects of cyto-skeleton on distribution and as targets for selective killing. Cancer Cells I. 1984;75-86.
  • Bernal SD and Speak JA.
    Membrane antigen in small cell carcinoma of the lung defined by monoclonal antibody SM1. Cancer Res. 1984;4:265-270.
  • Stahel RA, Mabry M, Skarin AT, Speak JA and Bernal SD.
    Detection of bone marrow metastasis in small cell lung cancer by monoclonal antibodies. J Clin Onc. 1985;3:455-461.
  • Stahel RA, Speak JA and Bernal SD.
    Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas. Int J Cancer. 1985;35:11-17.
  • Stahel RA, Mabry M, Sabath D, Speak JA and Bernal SD.
    Selective cytotoxicity of murine monoclonal antibody LAM2 against human small cell carcinoma in the presence of human complement. Int J of Cancer. 1985;35:587-592.
  • Bernal SD, Mabry M, Stahel RA, Griffin JD and Speak JA.
    Selective cytotoxicity of SM1 monoclonal antibody toward small cell carcinoma of the lung. Cancer Res. 1985;45:1026-1032.
  • Mabry M, Speak JA, Griffin JD, Stahel RA and Bernal SD.
    The use of SM1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest. 1985;75:1690-1695.
  • Boheim K, Speak JA, Frei E. III and Bernal SD.
    SQM1 antibody defines a surface membrane antigen in squamous carcinomas of the head and neck. Int J of Cancer. 1985;36:137-142.
  • Frei E III, cucchi CA, Rosowsky A, Tantravahi R, Bernal SD, Ervin TJ, Ruprecht RM and Haseltine WA.
    Alkylating agent resistance: in vitro studies with human cell lines. Proc. Natl. Acad. Sci. USA. 1985;82:2158-2162.
  • Boheim K, Schwarzfurtner H, Boheim C, Frei E III and Bernal SD.
    Immunohistochemical identification of squamous carcinoma of the head and neck with monoclonal antibody SQM1. Acta Otolaryngol. 1986;102:333-340.
  • Gibas A, Li FP, Antman KH, Bernal SD, Stahel RA and Sandberg AA.
    Chromosome changes in malignant mesothelioma. Cancer Gnet Cytogenet. 1986;20:191-201.
  • Stahel RA, O'Hara CJ, Mabry M, Sabbath K, Speak JA and Bernal SD.
    Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung. Cancer Res. 1986;46:2077-2084.
  • Boheim K, Boheim C, Frei E III and Bernal SD.
    Assessment of squamous carcinomas of the head and neck with monoclonal antibody SQM1. Immunobiology. 1987;4/5:341-346.
  • Bernal SD, Cualing H, Elias A and Siegel R.
    Stability and shedding of small cell carcinoma membrane antigens: applications to detection of antigens in marrow and serum. Lung Cancer Journal. 1988;4: 79-80.
  • Bernal SD,Weinberg K, Kakefuda M, Stahel R, O'Hara C and Wong Y-C.
    Membrane antigens of human bronchial epithelial cells identified by monoclonal antibodies. In Vitro Cellular & Developmental Biology. 1988;24(2):117-125.
  • Elias AD, Cohen BF and Bernal SD.
    The keratins of small cell lung cancer of the lung (SCLC). Cancer Research. 1988;48:2724-2729.
  • Elias AD, Cohen B and Bernal SD.
    Monoclonal antibodies recognizing cytoskeletal proteins of small cell lung carcinoma. 
    Lung Cancer Journal. 1988;4:82-85.
  • Dreyfuss A, Speak J and Bernal SD.
    Localization of radiolabeled SMI monoclonal antibody to small-cell lung cancer tumors in mice. Hybridoma. 1988;7:1-6.
  • Bernal SD, Cualing H, Elias A, Schwarting G and McCluer R.
    Classification of small cell carcinoma antigens by their association with subcellular components. Lung Cancer Journal. 1988;4:99-102.
  • Teicher BA, Bernal SD, Holden and Cathcart K.
    Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Cancer Chemotherapy & Pharmacology. 1988;21:281-285.
  • Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P,  Sallan SE,and Cohen HJ.
    In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49:4363-4368.
  • Tsao SW, Chew EC, Yam HF and Bernal SD.
    Ultrastructural localization of a new surface membrane antigen (SQM1) related to squmaous differentiation. In Vivo. 1989;3:367-374.
  • Elias AD, Pap SA and Bernal SD.
    Purging of small cell lung cancer-contaminated bone marrow by monoclonal antibodies and magnetic beads. Prog Clin Biol Res. 1990;333:263-275.
  • Wong YC and Bernal SD.
    Differential utilization of the SV40 enhancer and early promoter in various human lung carcinoma cell lines. Int J Cancer. 1990;45:911-915.
  • Wong Y-C, Tsao SW, Kakefuda M, Bernal SD.
    cDNA cloning of a novel cell adhesion protein expressed in human squamous carcinoma cells. Biochem Biophys Res Commun. 1990;166:984-992.
  • Bernal SD, Speak JA, Boeheim K, Dreyfuss AI, Wright JE, Teicher BA, Rosowsky A, Tsao SW and Wong Y-C.
    Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem. 1990;95:61-70.
  • Chew EC, Yam HF, Tsao SW and Bernal SD.
    Expression of a new surface membrane antigen (SQM1) in tumor cells cultured in media with different calcium ion levels. Anticancer Research. 1991;11:2-11,1205-1214.
  • Wong Y-C and Bernal SD.
    Expression of enhancer binding factors associated with various cell types of lung cancer. Biochem Biophys Res Commun. 1991; 1064-1069.
  • Cualing H, Siegel R, Schwarting GA, Suchy SF, McCluer RH and Bernal SD.
    The expression of H-like blood group glycopipids in small     cell carcinoma of the lung. Hybridoma. 1993;112:239-247.
  • DeCastro-Bernas G, Wong Y-C and Bernal SD.
    Developmentally regulated expression of membrane adhesion protein (SQM1) in normal bronchial epithelial cells. Asia Pacific Journal of Molecular Biology and Biotechnology. 1993;1:70-82.
  • Wong Y-C and Bernal SD.
    Multiple NF-I-site binding factors associated with different cell-types of human lung carcinomas. Anticancer Research, 1994;14:593-596.
  • Bernal SD,  DeVilla RS, and Wong Y-C.
    Congruence of SQM1 protein expression with methotrexate sensitivity and transport. Cancer Investigation, 1995; 12(1), 23-30.
  • Wong Y-C, Kakefuda M, and Bernal SD.
    A new membrane marker or commitment of normal human bronchial epithelial cells to squamous differentiation. In Vivo, 1997; Vol 11, No. 6.
  • Induction of membrane expression of a differentiation membrane protein by calcium.
  • G. DeCastro-Bernas, M. Kakefuda, Y-C Wong, and S.D. Bernal. A-P Journal of and Biotechnology.1999; 2:24.
  • Prognostic Significance of Early Response to a Single Dose of Asparaginase in Childhood Acute Lymphoblastic Leukemia
  • Barbara L. Asselin, Susan Kreissman, David J. Coppola, Samuel D. Bernal, Pearl R. Leavitt, Richard D. Gelber, Stephen E. Sallan, and Harvey J. Cohen. Journal of  Pediatric Hematology/Oncology, 1999; Vol. 21. No. 1    
  • Wong and S.D. Bernal
    Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome Anticancer Res. 1999; 19(A); 251-254.

    Book Chapters:

    1. Mitochondria and cytoskeleton of human tumor cells.
    Chen LB, Lampidis TL, Bernal SD, Nadakavukaren KK and Summerhayes IC.
    Genes and Proteins in Oncogenesis
    Edited by Weinstein and Vogel
    Academic Press, 1983;369-387.

    2. Small Cell Carcinoma Antigens
    Bernal SD, Cualing HM, Stahel RA, Elias A, and Mabry M.
    Diagnosis and Treatment of Lung Cancer
    Lung Biology in Health and Disease by C. Lenfant
    Edited by P.G. Abrams, S.T. Rosen
    Marcel Dekker, Inc., New York, 1988, 37:213-236.

    3. The Use of Monoclonal Antibodies to Purge Bone Marrow in the Treatment of Lung Cancer.
    Stahel RA, Mabry M, and Bernal SD.
    Diagnosis and Treatment of Lung Cancer
    Lung Biology in Health and Disease by C. Lenfant
    Edited by P.G. Abrams, S.T. Rosen
    Marcel Dekker, Inc., New York, 1988, 37:255-274.

    4. Differentiation and Drug Resistance in Lung Cancer
    Bernal SD, Wong Y-C, Kakefuda M and Urbano AG.
    Biology of Lung Cancer
    Edited by S.D. Bernal and P.H. Hesketh
    Marcel Dekker, Inc., New York, 1992.

    5. Enhancer Binding Proteins in Lung Cancer
    Bernal SD, Wong Y-C, Kakefuda M and Urbano AG
    Biology of Lung Cancer
    Edited by S.D. Bernal and P.H. Hesketh
    Marcel Dekker, Inc., New York, 1992.

    6. A New Membrane Protein Associated with Resistance to Cis-platinum and Methotrexate
    Bernal SD, Wong Y-C, Kakefuda M and Urbano AG.
    Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
    Plenum Press, New York, 1992, pp323-324.

    7. Liposomal Formulations of Chemotherapeutic Drugs.
    Bernal SD Wong Y-C, DeVilla RS, and Bernas, G.
    Drug Resistance in Oncology
    Edited by S.D. Bernal
    Marcel Dekker, Inc., New York, 1997.

This website uses information-gathering tools, such as cookies, web analytics, and other similar technology. By using this website, you consent to the use of these tools.

View Privacy Policy